March 2011 in “Cancer Epidemiology Biomarkers & Prevention” SLCO genes may predict prostate cancer mortality risk, and lifestyle changes improve health in advanced prostate cancer.
Finasteride may help prevent prostate cancer, but more research is needed.
228 citations
,
February 2003 in “Urology” Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.
10 citations
,
June 2010 in “Expert Opinion on Drug Metabolism & Toxicology” Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
1 citations
,
October 2006 in “Oncology times” Finasteride improves prostate cancer detection in PSA test.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
January 2009 in “The Hastings Center Report” Finasteride reduces prostate cancer risk but may increase high-grade cancer risk.
October 2006 in “The Lancet Oncology” Finasteride reduces prostate cancer risk but may increase aggressive cancer risk slightly.
January 2006 in “Revista Argentina de Urología” Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.
September 2004 in “Urology” Dutasteride may help prevent prostate cancer, but more research is needed.
April 2004 in “Medisch-Farmaceutische Mededelingen” Finasteride may help reduce prostate cancer risk.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
3 citations
,
January 2023 in “Clinical cancer investigation journal” Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
September 2013 in “Cancer Discovery” Finasteride is safe for long-term use in prostate cancer treatment.
29 citations
,
October 1988 in “Journal of Steroid Biochemistry” Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
3 citations
,
September 2013 in “Urology” More biopsy cores and MRI before biopsy can improve prostate cancer detection.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
1 citations
,
April 2014 in “Journal of the Korean Society of Food Science and Nutrition” Unripe Rubus occidentalis extracts may help treat benign prostatic hyperplasia.
1 citations
,
April 2008 in “Progrès en Urologie” Finasteride shows promise for preventing prostate cancer, but more research is needed.
June 2023 in “Oriental Journal of Chemistry/Oriental journal of chemistry” New compounds may help treat prostate cancer by reducing cell growth.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
Higher PSA levels can indicate prostate cancer, but there's overlap with non-cancerous conditions.
5-ARI therapy may help prevent prostate cancer progression.
April 2012 in “The Journal of Urology” PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
November 2011 in “InTech eBooks” Selenium shows promise in preventing and controlling prostate cancer.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
Finasteride significantly reduces the risk of prostate cancer.
May 2008 in “Nature Clinical Practice Urology” Finasteride may be cost-effective for preventing prostate cancer in high-risk groups.